CXCR4 receptor antagonists - Pipeline Insight, 2022
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “CXCR4 Receptor Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in CXCR4 Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
CXCR4 Receptor Antagonists: Overview
CXCR4 is a 352 amino acid rhodopsin-like GPCR, comprising an extracellular N-terminal domain, 7 transmembrane (TM) helices, 3 extra-cellular loops (ECL), 3 intra-cellular loops (ICL) and an intracellular C-terminal domain. CXCR4 can exist in the plasma membrane as a monomer, dimer, higher-order oligomer or nanoclusters.
Function - CXCR4 can control cell proliferation in addition to directing cell retention and movement, both in physiological processes, such as development and tissue regeneration, and in pathological ones, such as cancer growth. Signal transduction pathways downstream CXCR4 eventually control both cell movement and cell proliferation, which are both dependent on PI3K-Akt and mTORC signaling; the details, however, may vary from cell to cell and in different settings.
CXCR4 Receptor Antagonists - CXCR4 antagonists can disrupt adhesive tumor–stroma interactions and mobilize leukemia cells from their protective stromal microenvironment, making them more accessible to conventional drugs. Therefore, targeting the CXCR4-CXCL12 axis is a novel, attractive therapeutic approach that is explored in ongoing clinical trials in leukemia patients. Initially, CXCR4 antagonists were developed for the treatment of HIV, where CXCR4 functions as a co-receptor for virus entry into T cells. The diverse role of the SDF-1/CXCR4 axis in the pathogenesis of HIV, cancer, and rheumatoid arthritis, has established CXCR4 as a promising therapeutic target. Considering the vast population of patients with these diseases, the development of CXCR4 antagonists is of therapeutic as well as economic importance.
CXCR4 Receptor Antagonists Emerging Drugs Chapters
This segment of the CXCR4 Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
CXCR4 Receptor Antagonists Emerging Drugs
Further product details are provided in the report……..
CXCR4 Receptor Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different CXCR4 Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
CXCR4 Receptor Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CXCR4 Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CXCR4 Receptor Antagonists drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “CXCR4 Receptor Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in CXCR4 Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
CXCR4 Receptor Antagonists: Overview
CXCR4 is a 352 amino acid rhodopsin-like GPCR, comprising an extracellular N-terminal domain, 7 transmembrane (TM) helices, 3 extra-cellular loops (ECL), 3 intra-cellular loops (ICL) and an intracellular C-terminal domain. CXCR4 can exist in the plasma membrane as a monomer, dimer, higher-order oligomer or nanoclusters.
Function - CXCR4 can control cell proliferation in addition to directing cell retention and movement, both in physiological processes, such as development and tissue regeneration, and in pathological ones, such as cancer growth. Signal transduction pathways downstream CXCR4 eventually control both cell movement and cell proliferation, which are both dependent on PI3K-Akt and mTORC signaling; the details, however, may vary from cell to cell and in different settings.
CXCR4 Receptor Antagonists - CXCR4 antagonists can disrupt adhesive tumor–stroma interactions and mobilize leukemia cells from their protective stromal microenvironment, making them more accessible to conventional drugs. Therefore, targeting the CXCR4-CXCL12 axis is a novel, attractive therapeutic approach that is explored in ongoing clinical trials in leukemia patients. Initially, CXCR4 antagonists were developed for the treatment of HIV, where CXCR4 functions as a co-receptor for virus entry into T cells. The diverse role of the SDF-1/CXCR4 axis in the pathogenesis of HIV, cancer, and rheumatoid arthritis, has established CXCR4 as a promising therapeutic target. Considering the vast population of patients with these diseases, the development of CXCR4 antagonists is of therapeutic as well as economic importance.
CXCR4 Receptor Antagonists Emerging Drugs Chapters
This segment of the CXCR4 Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
CXCR4 Receptor Antagonists Emerging Drugs
- Burixafor: TaiGen Biotechnology
- USL311: Proximagen
Further product details are provided in the report……..
CXCR4 Receptor Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different CXCR4 Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on CXCR4 Receptor Antagonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
CXCR4 Receptor Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CXCR4 Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CXCR4 Receptor Antagonists drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence CXCR4 Receptor Antagonists R&D. The therapies under development are focused on novel approaches for CXCR4 Receptor Antagonists.
- CXCR4 Receptor Antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing CXCR4 Receptor Antagonists drugs?
- How many CXCR4 Receptor Antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for CXCR4 Receptor Antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CXCR4 Receptor Antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for CXCR4 Receptor Antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- TaiGen Biotechnology
- Proximagen
- AdAlta
- ChemoCentryx
- Polyphor
- BioLineRx
- X4 Pharmaceuticals
- GlycoMimetics
- Sanofi Genzyme
- Eli Lilly and Company
- Bristol-Myers Squibb
- Cantex Pharmaceuticals
- Altiris Therapeutics
- Burixafor
- USL311
- AD 214
- Research programme: chemokine receptor antagonists
- Balixafortide
- Motixafortide
- X4P-003
- Mavorixafor
- GMI 1359
- Plerixafor
- LY 2510924
- Ulocuplumab
- Dociparstat sodium
- Q 122
Introduction
Executive Summary
CXCR4 Receptor Antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
CXCR4 Receptor Antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
CXCR4 Receptor Antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
CXCR4 Receptor Antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Motixafortide: BioLineRx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Burixafor: TaiGen Biotechnology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
USL311: Proximagen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
X4P-003: X4 Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
CXCR4 Receptor Antagonists Key Companies
CXCR4 Receptor Antagonists Key Products
CXCR4 Receptor Antagonists- Unmet Needs
CXCR4 Receptor Antagonists- Market Drivers and Barriers
CXCR4 Receptor Antagonists- Future Perspectives and Conclusion
CXCR4 Receptor Antagonists Analyst Views
CXCR4 Receptor Antagonists Key Companies
Appendix
Executive Summary
CXCR4 Receptor Antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
CXCR4 Receptor Antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
CXCR4 Receptor Antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
CXCR4 Receptor Antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Motixafortide: BioLineRx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Burixafor: TaiGen Biotechnology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
USL311: Proximagen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
X4P-003: X4 Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
CXCR4 Receptor Antagonists Key Companies
CXCR4 Receptor Antagonists Key Products
CXCR4 Receptor Antagonists- Unmet Needs
CXCR4 Receptor Antagonists- Market Drivers and Barriers
CXCR4 Receptor Antagonists- Future Perspectives and Conclusion
CXCR4 Receptor Antagonists Analyst Views
CXCR4 Receptor Antagonists Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for CXCR4 Receptor Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for CXCR4 Receptor Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for CXCR4 Receptor Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for CXCR4 Receptor Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products